Retraction: Downregulation of ROS-FIG inhibits cell proliferation, colony-formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells (International Journal of Molecular Medicine (2014) 34 (661-668) DOI: 10.3892/ijmm.2014.1823);Downregulation of ROS-FIG inhibits cell proliferation, colony-formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells

International Journal of Molecular Medicine

Volumn 34, Issue 3, 2014, Pages 661-668

  Deng, Gang ^a   Hu, Chenghuan ^b   Zhu, Lei ^a   Huang, Feizhou ^a   Huang, Wei ^a   Xu, Hongbo ^a   Nie, Wanpin ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Fused in glioblastoma c ros oncogene1; HUCCT1 cell; Intrahepatic cholangiocarcinoma; Oncogene

Indexed keywords

FUSED IN GLIOBLASTOMA C ROS ONCOGENE 1; PROTEIN; PROTEIN FIG 363; PROTEIN KINASE B; PROTEIN ROS1 6290; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; FIG-ROS1 FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; FUSION GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR BIOLOGY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BILE DUCT TUMOR; CELL CYCLE; CELL MOTION; DOWN REGULATION; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY;

EID: 84905016551     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2023.5335     Document Type: Erratum

References (26)

1. McLean L and Patel T: Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 26: 1047-1053, 2006. (Pubitemid 44541745)
2. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 (Suppl 6): VI1-VI9, 2002. (Pubitemid 35216840)
3. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, et al: Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248: 84-96, 2008.
4. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, et al: Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 44: 690-693, 2012.
5. Gu TL, Deng X, Huang F, Tucker M, Crosby K, et al: Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6: e15640, 2011.
6. Charest A, Lane K, McMahon K, Park J, Preisinger E, et al: Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6) (q21q21). Genes Chromosomes Cancer 37: 58-71, 2003. (Pubitemid 36417922)
7. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS and Lowe SW: Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci USA 110: 19513-19518, 2013.
8. Shaw AT, Camidge DR, Engelman JA, et al: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30: abstr 7508, 2012.
9. Sirica AE, Zhang Z, Lai GH, Asano T, Shen XN, et al: A novel 'patient-like' model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47: 1178-1190, 2008. (Pubitemid 351547904)
10. Malhi H and Gores GJ: Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45: 856-867, 2006. (Pubitemid 44646688)
11. Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15, 2005.
12. Malhi H and Gores GJ: Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45: 856-867, 2006. (Pubitemid 44646688)
13. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-381, 2012.
14. Lira ME, Choi YL, Lim SM, Deng S, Huang D, et al: A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. J Mol Diagn 16: 229-243, 2014.
15. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870, 2012.
16. Nagarajan L, Louie E, Tsujimoto Y, Balduzzi PC, Huebner K and Croce CM: The human c-ros gene (ROS) is located at chromosome region 6q16-6q22. Proc Natl Acad Sci USA 83: 6568-6572, 1986. (Pubitemid 17174776)
17. Jun HJ, Woolfenden S, Coven S, Lane K, Bronson R, et al: Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer Res 69: 2180-2184, 2009.
18. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203, 2007. (Pubitemid 350235027)
19. Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, et al: ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/ phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 66: 7473-7481, 2006. (Pubitemid 44289201)
20. Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, et al: Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA 110: 19519-19524, 2013.
21. Farnebo M, Bykov VJ and Wiman KG: The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396: 85-89, 2010.
22. Mork CN, Faller DV and Spanjaard RA: A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 11: 1091-1104, 2005. (Pubitemid 40403370)
23. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, et al: Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One 8: e82236, 2013.
24. Acquaviva J, Wong R and Charest A: The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 1795: 37-52, 2009.
25. Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, et al: Leptin enhances cholangiocarcinoma cell growth. Cancer Res 68: 6752-6761, 2008.
26. Yoon H, Min JK, Lee JW, Kim DG and Hong HJ: Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun 405: 333-337, 2011.